期刊文献+

原发性乳腺弥漫性大B细胞淋巴瘤4例临床病理分析

Clinicopathological analysis of 4 cases of primary breast diffuse large B-cell lymphoma
下载PDF
导出
摘要 目的:探究原发性乳腺弥漫性大B细胞淋巴瘤(Primary breast diffuse large B-cell lymphoma,PB-DLBCL)的临床病理特征、鉴别诊断及治疗预后。方法:收集右江民族医学院附属医院病理科2017年1月至2020年12月就诊的4例PB-DLBCL患者的相关临床资料、病理组织切片及免疫组化表型并结合相关文献进行分析。结果:4例均为中青年女性,年龄38~56岁,均因乳腺无痛性增大包块就诊,左乳2例,右乳2例。3例为非生发中心型,1例为生发中心型。根据Ann Arbor分期标准:Ⅰ期3例,Ⅱ期1例。镜检:乳腺正常结构被破坏,中等大小的圆形或卵圆形肿瘤细胞弥漫分布,胞质少至丰富,嗜碱性,核仁可见,核分裂像易见。免疫组化:CD19、CD20、CD79a、PAX5(+),部分病例CD10、BCL-6及BCL-2(+),Ki-67增殖指数85%~90%。随访至2021年7月,1例失访,1例死亡,2例健在。结论:PB-DLBCL发病率低,临床症状及影像学表现无特殊,预后差,确诊需结合病理组织形态学及免疫表型。 Objective:To investigate the clinicopathological features,differential diagnosis,treatment and prognosis of primary breast diffuse large B-cell lymphoma(PB-DLBCL).Methods:Four cases of PB-DLBCL were collected(from January,2017 to December 2020,in the department of pathology,The Affiliated Hospital of Youjiang Medical University for Nationalities),the relevant clinical data,pathological sections and immunohistochemical phenotypes of the patients were analysed combined with relevant literature.Results:All of the 4 patients were middle-aged women with an onset age of 38-56 years old.They were all treated for painless enlargement of breast mass,including 2 cases of left breast and 2 cases of right breast,3 cases were non-GCB,1 case GCB.According to Ann Arbor staging criteria,3 cases were stageⅠ,1 case was stageⅡ.Under the microscope,the normal structure of mammary gland was destroyed,the mediumsized,round or oval tumor cells were diffusely distributed,with less to rich cytoplasm,basophilic,with visible nucleolus and mitotic figures.According to the immunohistochemical phenotype,CD19、CD20、CD79a、PAX5 were positive,in some cases,CD10、BCL6 and BCL-2 were positive.Ki-67 proliferation indexes were from 85%to 90%.The followup time of the cases was up to July 2021,and 1 patient was lost to follow-up,1 patient died and 2 patients were still alive.Conclusion:The incidence of PB-DLBCL is low.The clinical symptoms and imaging features are not special,and the prognosis is poor.The diagnosis should be combined with histopathology and immunophenotype.
作者 潘秋璐 杨广红 吴雪铭 龙喜带 黄炳臣 黄小英 PAN Qiu-lu;YANG Guang-hong;WU Xue-ming;LONG Xi-dai;HUANG Bing-chen;HUNANG Xiao-ying(Youjiang Medical University for Nationlities;Department of Pathology,The Affiliated Hospital of Youjiang Medical University for Nationalities,Baise,Guangxi 533000;Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region,Nanning,Guangxi 530000;Youjiang Medical University for Nationlities,Baise,Guangxi 533000)
出处 《赣南医学院学报》 2022年第4期362-366,共5页 JOURNAL OF GANNAN MEDICAL UNIVERSITY
基金 广西壮族自治区自然科学基金项目(2017GXNSFAA198002)。
关键词 乳腺肿瘤 原发性乳腺弥漫大B细胞淋巴瘤 Breast tumors Primary breast diffuse large B-cell lymphoma
  • 相关文献

参考文献7

二级参考文献31

  • 1Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BcI2 protein co- expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high- risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program [ J]. Blood, 2013, 121 (20) :4021-4031.
  • 2Perry AM, Crockett D, Dave B J, et al. B - cell lymphoma, un- elassifiable, with features intermediate between diffuse large B - cell lymphoma and burkitt lymphoma: study of 39 eases [ J]. Br J Haematol, 2013, 162( 1 ) :40-49.
  • 3Johnson NA, Slack GW, Savage IQ, et al. Concurrent expression of MYC and Bcl2 in diffuse large B-cell lymphoma treated with rit- uximab plus cyelophosphamide, doxorubiein, vineristine, and prednisone [J]. J Clin Oneol, 2012, 30(28):3452-3459.
  • 4Rantanen S, Monni O, Joensuu H, et al. Causes and conse- quences of Bel2 overexpression in diffuse large B-cell lymphoma ~J]. Leuk Lymphoma, 2001,42(5) :1089-1098.
  • 5Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by im- munohistoehemislry using a tissue microarray [ J]. Blood, 2004, 103(1 ) :275-282.
  • 6Wilson WH, Dunleavy K, Pittaluga S, et al. Phase lI study ofdose-adjusted EPOCH and rituximab in untreated diffuse large B- cell lymphoma with analysis of germinal center and post-germinal center biornarkers [J]. J Clin Oneol, 2008,26(16) :2717-2724.
  • 7Choi WW , Weisenburger DD, Greiner T C, et al. A new immu- nostain algorithm classifies diffuse large B-cell lymphoma into mo- lecular subtypes with high accuracy [ J]. Clin Cancer Res, 2009, 15(17) :5494-5502.
  • 8Gareia-SuOrez J, Flores E, Callejas M,et al. Two weekly dose-ad- justed DA -EPOCH-like chemotherapy with high dose dexameha- sone plus rituximab (DA-EDOCHI4-R)in poor-prognostic untreat- ed diffuse large B-cell lymphoma [J]. Br J Haematal, 2013,160 (4) :510-514.
  • 9Pittaluga S, Shovlin M, Pack S, et al. Concurrent Expression Of MYC/Bel-2 protein in newly diagnosed DLBCL is Not associated with an inferior survival following EPOCH-R therapy[J]. Blood, 2013, 122(21 ) : 3029-9.
  • 10Gatter K, Warnke RA. l)iffuse large B-cell lymphoma. In: Jaffe E S, Stein H, Vardiman J W, eds. World Health Organization clas- sification nf lumors: pathology and genetics of tumors of haemato- poietic and lymphoid tissues [ M]. Lyon: IARC Press, 2001.

共引文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部